Top

Cancer Cell International

Published in:

Open Access 01-12-2022 | Gastric Cancer | Primary research

miR-223-3p carried by cancer-associated fibroblast microvesicles targets SORBS1 to modulate the progression of gastric cancer

Authors: Xiaoli Jin, Xi Qiu, Yi Huang, Hang Zhang, Kaibo Chen

Published in: Cancer Cell International | Issue 1/2022

Abstract

Background

Cancer-associated fibroblasts (CAFs) aggravate gastric cancer (GC) development.

Methods

Combined with bioinformatics analysis and literature review, miR-223-3p had high expression in microvesicles (MVs) derived from GC CAFs, and it could modulate SORBS1. miR-223-3p and SORBS1 mRNA levels were assessed by qRT-PCR. The levels of CAFs markers, MVs markers, epithelial-mesenchymal transition (EMT)-associated proteins, and SORBS1 protein were assessed by western blot. MVs isolated from fibroblasts were observed by transmission electron microscopy. Combined with immunofluorescence and co-culture experiments, GC cells were determined to absorb MVs carrying miR-223-3p. Cell functions were measured using CCK-8, transwell, flow cytometry and colony formation assays. The binding of miR-223-3p and SORBS1 was determined by dual-luciferase assay and RNA immunoprecipitation. The cancer-promoting effect of MVs carrying miR-223-3p on experimental animals was verified in vivo by tumor-bearing experiment in nude mice.

Results

miR-223-3p was upregulated in the MVs secreted by GC CAFs and could be transmitted to GC cells through MVs, to boost the malignant progression of tumor cells. Additionally, it was also revealed that miR-223-3p targeted SORBS1 and accelerated progression along with EMT in GC.

Conclusions

CAFs-derived MVs could carry miR-223-3p to GC cells to target SORBS1, thereby promoting the malignant progression of GC.

Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet (London, England). 2020;396:635–48. https://doi.org/10.1016/s0140-6736(20)31288-5.CrossRef

Allemani C, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023–75. https://doi.org/10.1016/S0140-6736(17)33326-3.CrossRefPubMedPubMedCentral

Ham IH, Lee D, Hur H. Role of cancer-associated fibroblast in gastric cancer progression and resistance to treatments. J Oncol. 2019;2019:6270784. https://doi.org/10.1155/2019/6270784.CrossRefPubMedPubMedCentral

Erdogan B, Webb DJ. Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc Trans. 2017;45:229–36. https://doi.org/10.1042/BST20160387.CrossRefPubMedPubMedCentral

Wu S, Ju GQ, Du T, Zhu YJ, Liu GH. Microvesicles derived from human umbilical cord Wharton’s jelly mesenchymal stem cells attenuate bladder tumor cell growth in vitro and in vivo. PLoS ONE. 2013;8: e61366. https://doi.org/10.1371/journal.pone.0061366.CrossRefPubMedPubMedCentral

Rezaie Z, Ardeshirylajimi A, Ashkezari MD, Seifati SM. Antitumoral potential of microvesicles extracted from human adipose-derived mesenchymal stem cells on human breast cancer cells. J Cancer Res Ther. 2019;15:1114–9. https://doi.org/10.4103/jcrt.JCRT_147_18.CrossRefPubMed

Rahmani Kukia N, Alipanah-Moghadam R, Delirezh N, Mazani M. mesenchymal stromal stem cell-derived microvesicles enhance tumor lysate pulsed dendritic cell stimulated autologous T lymphocyte cytotoxicity. APJCP. 2018;19:1895–902. https://doi.org/10.22034/apjcp.2018.19.7.1895.CrossRefPubMed

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97. https://doi.org/10.1016/s0092-8674(04)00045-5.CrossRefPubMed

Wei Y, et al. MiR-223-3p targeting SEPT6 promotes the biological behavior of prostate cancer. Sci Rep. 2014;4:7546. https://doi.org/10.1038/srep07546.CrossRefPubMedPubMedCentral

10.

Ding Q, et al. MiR-223-3p overexpression inhibits cell proliferation and migration by regulating inflammation-associated cytokines in glioblastomas. Pathol Res Pract. 2018;214:1330–9. https://doi.org/10.1016/j.prp.2018.05.012.CrossRefPubMed

11.

Zhu Y, et al. miR-223-3p promotes cell proliferation and invasion by targeting Arid1a in gastric cancer. Acta Biochim Biophys Sin (Shanghai). 2020;52:150–9. https://doi.org/10.1093/abbs/gmz151.CrossRef

12.

Matson SA, Pare GC, Kapiloff MS. A novel isoform of Cbl-associated protein that binds protein kinase A. Biochem Biophys Acta. 2005;1727:145–9. https://doi.org/10.1016/j.bbaexp.2004.12.004.CrossRefPubMed

13.

Kioka N, Ueda K, Amachi T. Vinexin, CAP/ponsin, ArgBP2: a novel adaptor protein family regulating cytoskeletal organization and signal transduction. Cell Struct Funct. 2002;27:1–7. https://doi.org/10.1247/csf.27.1.CrossRefPubMed

14.

Zhang M, et al. CAP interacts with cytoskeletal proteins and regulates adhesion-mediated ERK activation and motility. EMBO J. 2006;25:5284–93. https://doi.org/10.1038/sj.emboj.7601406.CrossRefPubMedPubMedCentral

15.

Song L, et al. SORBS1 suppresses tumor metastasis and improves the sensitivity of cancer to chemotherapy drug. Oncotarget. 2017;8:9108–22. https://doi.org/10.18632/oncotarget.12851.CrossRefPubMed

16.

Li J, et al. MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4. J Cancer Res Clin Oncol. 2012;138:763–74. https://doi.org/10.1007/s00432-012-1154-x.CrossRefPubMed

17.

Loh CY, et al. The E-Cadherin and N-Cadherin switch in epithelial-to-mesenchymal transition signaling, therapeutic implications, and challenges. Cells. 2019. https://doi.org/10.3390/cells8101118.CrossRefPubMedPubMedCentral

18.

De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017;17:457–74. https://doi.org/10.1038/nrc.2017.51.CrossRefPubMed

19.

Ren N, et al. LncRNA ADAMTS9-AS2 inhibits gastric cancer (GC) development and sensitizes chemoresistant GC cells to cisplatin by regulating miR-223-3p/NLRP3 axis. Aging (Albany NY). 2020;12:11025–41. https://doi.org/10.18632/aging.103314.CrossRef

20.

Wang J, et al. Hsa_circ_0003159 inhibits gastric cancer progression by regulating miR-223-3p/NDRG1 axis. Cancer Cell Int. 2020;20:57. https://doi.org/10.1186/s12935-020-1119-0.CrossRefPubMedPubMedCentral

21.

Szatanek R, et al. Autologous tumorderived microvesicles influence gene expression profiles and enhance protumorigenic chemotactic potential, signal transduction and cellular respiration in gastric cancer cells. Int J Oncol. 2020;56:359–67. https://doi.org/10.3892/ijo.2019.4923.CrossRefPubMed

22.

Baran J, et al. Circulating tumour-derived microvesicles in plasma of gastric cancer patients. Cancer Immunol Immunother. 2010;59:841–50. https://doi.org/10.1007/s00262-009-0808-2.CrossRefPubMed

23.

Stec M, et al. Interactions of tumour-derived micro(nano)vesicles with human gastric cancer cells. J Transl Med. 2015;13:376. https://doi.org/10.1186/s12967-015-0737-0.CrossRefPubMedPubMedCentral

24.

Yu W, et al. MiR-142-5p acts as a significant regulator through promoting proliferation, invasion, and migration in breast cancer modulated by targeting SORBS1. Technol Cancer Res Treat. 2019;18:1533033819892264. https://doi.org/10.1177/1533033819892264.CrossRefPubMedPubMedCentral

Title: miR-223-3p carried by cancer-associated fibroblast microvesicles targets SORBS1 to modulate the progression of gastric cancer
Authors: Xiaoli Jin
Xi Qiu
Yi Huang
Hang Zhang
Kaibo Chen
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Gastric Cancer
Gastric Cancer
Published in: Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-022-02513-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Prostate cancer in omics era

Advances in biomarkers and techniques for pancreatic cancer diagnosis

Potential use of EGFR-targeted molecular therapies for tumor suppressor CYLD-negative and poor prognosis oral squamous cell carcinoma with chemoresistance

Pan-cancer analysis combined with experiments explores the oncogenic role of spindle apparatus coiled-coil protein 1 (SPDL1)

CD5L-associated gene analyses highlight the dysregulations, prognostic effects, immune associations, and drug-sensitivity predicative potentials of LCAT and CDC20 in hepatocellular carcinoma

Association of delayed chemoradiotherapy with elevated Epstein-Barr virus DNA load and adverse clinical outcome in nasopharyngeal carcinoma treatment during the COVID-19 pandemic: a retrospective study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer